Need Help?

Cancer treatment response monitoring of CAIRO5 patients with metastatic CRC using cell-free DNA (cfDNA) sequencing

Colorectal cancer (CRC) patients with unresectable liver-only metastases may be cured after downsizing of metastases by neoadjuvant systemic therapy. The CAIRO5 study is a Dutch prospective phase III clinical trial (NCT02162563) that investigated the optimal neoadjuvant induction regimen. Blood samples from CAIRO5 patients were used to assess whether cell-free circulating tumor DNA could be used for treatment response monitoring. The following studies have been performed: 1. Perform cancer treatment response monitoring by combining ultra-deep targeted sequencing analyses of cfDNA with patient-matched white blood cell (WBC) derived DNA. In total, 183 cfDNA and 49 WBC samples, along with 28 FFPE tumor tissue samples, from 52 CAIRO5 patients were analyzed using the PGDx elio plasma resolve assay (33 gene panel). PMID: 36534496 2. Perform cancer treatment response monitoring using cfDNA fragmentomes. In total, 689 cfDNA samples from 153 CAIRO5 patients were analyzed using the DELFI-TF assay (8x WGS). PMID: 39433569

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001009718 NextSeq 500 101
EGAD00001009719 NextSeq 500 183
EGAD00001009720 NextSeq 500 28
EGAD00001009721 NextSeq 500 49
EGAD50000000630 Illumina NovaSeq 6000 689
Publications Citations
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
Clin Cancer Res 29: 2023 899-909
8
Cancer treatment monitoring using cell-free DNA fragmentomes.
Nat Commun 15: 2024 8801
0